Literature DB >> 16610770

SGN-30 (Seattle genetics).

Roland Schnell1, Peter Borchmann.   

Abstract

Seattle Genetics is developing SGN-30, an intravenously administered recombinant anti-CD30 monoclonal antibody for the potential treatment of Hodgkin's disease, certain non-Hodgkin's lymphomas, specific leukemia, and immunological diseases such as multiple sclerosis and systemic lupus erythematosus. Phase II trials in patients with Hodgkin's disease, anaplastic large cell lymphoma, and cutaneous lymphoma have been conducted in the U.S. and Europe.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16610770

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  3 in total

Review 1.  Immunotherapies for Hodgkin's lymphoma.

Authors:  Yvette L Kasamon; Richard F Ambinder
Journal:  Crit Rev Oncol Hematol       Date:  2007-11-19       Impact factor: 6.312

Review 2.  Manipulating B cell homeostasis: a key component in the advancement of targeted strategies.

Authors:  Laura S Treml; William J Quinn; John F Treml; Jean L Scholz; Michael P Cancro
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

3.  Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma.

Authors:  Ezogelin Oflazoglu; Kim M Kissler; Eric L Sievers; Iqbal S Grewal; Hans-Peter Gerber
Journal:  Br J Haematol       Date:  2008-05-08       Impact factor: 6.998
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.